Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.76 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.76 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626395 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL20626394 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL19583027 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL17825968 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL639975 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL639974 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL30716127 | 1.00 | SLC29A1 (1.00) | SLC29A1LMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL91169 | 0.92 | SLC29A1 (0.85) | SLC29A1TP53ADORA3TDP1PRKAG1 | |
| SCHEMBL20626300 | 0.91 | SLC29A1 (0.84) | SLC29A1TP53ADORA3TDP1PRKAG1 | |
| SCHEMBL15189026 | 0.91 | SLC29A1 (0.84) | SLC29A1TP53ADORA3TDP1PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | SLC29A1 267/4885LMNA 812/4885MAPT 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.